Ajinomoto Bio-Pharma Services vs City of Hope (T Cell Manufacturing): CDMO Comparison
How does Ajinomoto Bio-Pharma Services compare to City of Hope (T Cell Manufacturing) for Cell & Gene Therapy manufacturing?
Side-by-side comparison of Ajinomoto Bio-Pharma Services and City of Hope (T Cell Manufacturing) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- City of Hope (T Cell Manufacturing) has more FDA inspections on record (3 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Ajinomoto Bio-Pharma Services maintains 1 MHRA / UK GMP certificate; City of Hope (T Cell Manufacturing) does not.
- City of Hope (T Cell Manufacturing) appears as a manufacturing partner on more matched clinical programs (213 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and City of Hope (T Cell Manufacturing) qualify as Cell & Gene Therapy manufacturers; Ajinomoto Bio-Pharma Services carries the higher composite Signal Score for Cell & Gene Therapy programs in this comparison.
What to evaluate for Cell & Gene Therapy programs
Both Ajinomoto Bio-Pharma Services and City of Hope (T Cell Manufacturing) qualify as Cell & Gene Therapy CDMOs. When choosing between them for Cell & Gene Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
Frequently asked: Ajinomoto Bio-Pharma Services vs City of Hope (T Cell Manufacturing)
How does Ajinomoto Bio-Pharma Services compare to City of Hope (T Cell Manufacturing) for Cell & Gene Therapy manufacturing?
On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 86/100 and City of Hope (T Cell Manufacturing) is 84/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 3 for City of Hope (T Cell Manufacturing); European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 0 for City of Hope (T Cell Manufacturing). Both are tracked in the CDMO Signal directory as Cell & Gene Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or City of Hope (T Cell Manufacturing)?
Both Ajinomoto Bio-Pharma Services and City of Hope (T Cell Manufacturing) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; City of Hope (T Cell Manufacturing) has 3.
How do Ajinomoto Bio-Pharma Services and City of Hope (T Cell Manufacturing) compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. City of Hope (T Cell Manufacturing) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Ajinomoto Bio-Pharma Services or City of Hope (T Cell Manufacturing)?
Ajinomoto Bio-Pharma Services is matched to 0 ClinicalTrials.gov records as a manufacturing partner; City of Hope (T Cell Manufacturing) is matched to 213. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell & Gene Therapy manufacturing — Ajinomoto Bio-Pharma Services or City of Hope (T Cell Manufacturing)?
Both Ajinomoto Bio-Pharma Services and City of Hope (T Cell Manufacturing) are tagged as Cell & Gene Therapy CDMOs in our directory, so both are credible options for Cell & Gene Therapy programs. The most important differentiator for Cell & Gene Therapy selection is typically integrated vs point-solution cdmo: Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →